LEGAL PROCEEDINGS
−Removed: In May 2020, PeriphaGen, Inc.
−Removed: (“PeriphaGen”) commenced litigation against the Company alleging breach of contract and misappropriation of trade secrets.
−Removed: In April 2022, the Company and PeriphaGen entered into a final settlement.
−Removed: In accordance with the settlement agreement, the Company paid PeriphaGen total consideration of $75.0 million to settle the dispute, acquire certain assets and receive an exclusive license from PeriphaGen to certain intellectual property assets and biological materials which was paid over time upon completion of certain milestones.
−Removed: Refer to Note 7 of our consolidated financial statements in our 2024 10-K for additional information.
−Removed: The Company recorded litigation settlement expense of zero and $12.5 million for the three months ended June 30, 2025 and 2024, respectively, on the condensed consolidated statements of operations and comprehensive income.
−Removed: During the three months ended March 31, 2025 and 2024, the Company paid $31.25 million and zero, respectively, and as such, the Company has fully paid the $75.0 million of total consideration discussed above.
−Removed: We are not currently a party to any material legal proceedings.
−Removed: We may, however, in the ordinary course of business face various claims brought by third parties or government regulators and, from time to time, make claims or take legal actions to assert our rights, including claims relating to our directors, officers, stockholders, intellectual property rights, employment matters and the safety or efficacy of our products.
−Removed: Any of these claims could subject us to costly litigation and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage, may be inadequately capitalized to pay on valid claims, or our policy limits may be inadequate to fully satisfy any damage awards or settlements.
+Added: For discussion regarding legal proceedings, please refer to Note 7 of the notes to the consolidated financial statements in the 2024 10-K and Note 7 of the notes to the consolidated financial statements in this Quarterly Report on Form 10-Q for additional information.
+Added: In the ordinary course of business, we have faced, and we may in the future face, various claims brought by third parties or government regulators and, from time to time, make claims or take legal actions to assert our rights, including claims relating to our directors, officers, stockholders, intellectual property rights, employment matters and the safety or efficacy of our products.
+Added: Any of these claims have subjected and could in the future subject, us to costly litigation and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage, may be inadequately capitalized to pay on valid claims, or our policy limits may be inadequate to fully satisfy any damage awards or settlements.
If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated operations, cash flows and financial position.
Additionally, any such claims, whether or not successful, could damage our reputation and business.
+Added: There have been no material changes to the risk factors previously disclosed in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in Part II, Item 1A of our Quarterly Reports on Form 10-Q filed during 2025.
+Added: UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
+Added: DEFAULTS UPON SENIOR SECURITIES
+Added: MINE SAFETY DISCLOSURES
+Added: Not applicable.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.